In a study of U.S. Department of Veterans Affairs patients with hepatitis C (HCV), only a minority were willing to start treatment and fewer still achieved the undetectable viral loads that appear to be associated with decreased rates of illness and death, according to a study by JAMA Internal Medicine, a publication offered by The Journal of the American Medical Association.
HCV is estimated to affect as many as 170 million people worldwide and an estimated 3.2 million people in the United States. Patients with HCV are at risk of developing liver-related complications such as cirrhosis, liver failure and the cancer hepatocellular carcinoma, the authors wrote in the study background. However, sometimes patients with HCV go untreated because of adverse effects from available treatments.
Jeffrey McCombs of the USC School of Pharmacy and the USC Leonard D. Schaeffer Center for Health Policy & Economics, and colleagues sought to describe the progression of HCV in clinical practice by examining the time to liver-related clinical events and death in a group of 28,769 patients from the Veterans Affairs’ HCV clinical registry.
Of the patients, only 24.3 percent were willing to start treatment, and 16.4 percent of treated patients achieved an undetectable viral load. The study reported that death rates were 6.8 per 1,000 person-years for patients who achieved viral suppression versus 21.8 per 1,000 person-years in patients who did not meet that goal. Patients who achieved undetectable viral loads also reduced their risk of liver-related events by 27 percent, according to the results.
“While antiviral therapy can lead to viral eradication and reduced event risk, its effectiveness under real-world clinical conditions is limited by adverse effects and other factors,” the authors wrote. “In this study, only one in four patients with HCV and a detectable viral load were willing to initiate treatment. Once treated, only a fraction of patients achieved the minimum treatment response of a single undetectable viral load test.”
Financial support for the research was provided by Bristol-Myers Squibb.